The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province

YANG Jia-lu; LUO Yan-fang; SHAN Ren-hu; ZUO Zhi-gang; YU Zhen; CHEN Wu-nong; ZHU Yao-wen; LI Liu-qing; LUO Shi-yun; YE Yong-xin; ZHANG Zhuo-yu; LI Rui; JU Jing-meng; ZHU Shan-shan; FAN Jia-hua; XIA Min

doi:10.16462/j.cnki.zhjbkz.2021.10.011

Volume 25 Issue 10

Nov. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2021 > 25(10): 1175-1179, 1230

YANG Jia-lu, LUO Yan-fang, SHAN Ren-hu, ZUO Zhi-gang, YU Zhen, CHEN Wu-nong, ZHU Yao-wen, LI Liu-qing, LUO Shi-yun, YE Yong-xin, ZHANG Zhuo-yu, LI Rui, JU Jing-meng, ZHU Shan-shan, FAN Jia-hua, XIA Min. The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011

Citation:

YANG Jia-lu, LUO Yan-fang, SHAN Ren-hu, ZUO Zhi-gang, YU Zhen, CHEN Wu-nong, ZHU Yao-wen, LI Liu-qing, LUO Shi-yun, YE Yong-xin, ZHANG Zhuo-yu, LI Rui, JU Jing-meng, ZHU Shan-shan, FAN Jia-hua, XIA Min. The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011

Citation:

YANG Jia-lu, LUO Yan-fang, SHAN Ren-hu, ZUO Zhi-gang, YU Zhen, CHEN Wu-nong, ZHU Yao-wen, LI Liu-qing, LUO Shi-yun, YE Yong-xin, ZHANG Zhuo-yu, LI Rui, JU Jing-meng, ZHU Shan-shan, FAN Jia-hua, XIA Min. The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(10): 1175-1179, 1230. doi: 10.16462/j.cnki.zhjbkz.2021.10.011

PDF( 16007 KB)

The prevalence of the metabolic associated fatty liver disease among residents aged 30 to 79 in Dongguan City of Guangdong Province

doi: 10.16462/j.cnki.zhjbkz.2021.10.011

1.
Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, China
2.
Department of Public Health, Nancheng Community Health Service Center, Dongguan 523076, China
3.
Department of Prevention and Health, Chashan Community Health Service Center, Dongguan 523381, China
4.
Department of General Practice, Chashan Community Health Service Center, Dongguan 523381, China
5.
Department of Public Health, Dongcheng Community Health Service Center, Dongguan 523165, China

Funds:

National Key Research and Development Program of China 2017YFC0907100

More Information

Corresponding author: XIA Min, E-mail: xiamin@mail.sysu.edu.cn
Received Date: 2021-06-07
Rev Recd Date: 2021-09-15

Available Online: 2021-11-17

Publish Date: 2021-10-10

Abstract

Abstract

Objective To explore the prevalence of metabolic associated fatty liver disease (MAFLD) and the impact of different characteristics among residents aged 30 to 79 in Dongguan City of Guangdong Province. Methods Baseline data were collected in Dongguan City, Guangdong Province of South China Cohort, including physical examination, ultrasound, and laboratory tests. According to the inclusion and exclusion criteria, we included 8 670 participants and defined the status of MAFLD referred to the consensus statement of international experts. Multivariate Logistic regression analysis model was used to analyze the factors according to gender. Results The prevalence of MAFLD was 31.85% among residents aged 30 to 79 in Dongguan City. The prevalence was similar among males in different age groups (χ² =2.958, P=0.565), while it linearly increased with age in females (χ_trend²=81.429, P < 0.001). The prevalence showed a linear increase with BMI, FPG, ALT, TG, TC, uric acid (UA) while a linear decrease with HDL-C. The results of multivariate Logistic regression analysis model showed that females ≥50 years old had a higher risk of MAFLD (OR=2.37, 95% CI: 1.74~3.23, P < 0.001). Conclusions The prevalence of MAFLD was 31.85% among residents aged 30 to 79 in Dongguan City, and there was a linear association between the prevalence of MAFLD and various metabolic indices including BMI, FPG, TG, and TC. Age ≥50 years old may be a risk factor of MAFLD in females.
- Metabolic associated fatty liver disease,
- Prevalence,
- Residents

FullText(HTML)

References(22)

References

[1]	Nan Y, An J, Bao J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease[J]. J Hepatol, 2021, 75(2): 454-461. DOI: 10.1016/j.jhep.2021.05.003.
[2]	Zhou F, Zhou J, Wang W, et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: a systematic review and meta-analysis[J]. Hepatology, 2019, 70(4): 1119-1133. DOI: 10.1002/hep.30702.
[3]	Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease[J]. Gastroenterology, 2020, 158(7): 1999-2014. DOI: 10.1053/j.gastro.2019.11.312.
[4]	Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020, 73(1): 202-209. DOI: 10.1016/j.jhep.2020.03.039.
[5]	Xian YX, Weng JP, Xu F. MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy[J]. Chin Med J (Engl), 2020, 134(1): 8-19. DOI: 10.1097/CM9.0000000000001263.
[6]	Nabi O, Lacombe K, Boursier J, et al. Prevalence and risk factors of nonalcoholic fatty liver disease and advanced fibrosis in general population: the French Nationwide NASH-CO Study[J]. Gastroenterology, 2020, 159(2): 791-793. DOI: 10.1053/j.gastro.2020.04.048.
[7]	Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study[J]. J Gastroenterol, 2012, 47(5): 586-595. DOI: 10.1007/s00535-012-0533-z.
[8]	Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management[J]. Intern Med J, 2020, 50(9): 1038-1047. DOI: 10.1111/imj.14709.
[9]	Chen YL, Li H, Li S, et al. Prevalence of and risk factors for metabolic associated fatty liver disease in an urban population in China: a cross-sectional comparative study[J]. BMC Gastroenterol, 2021, 21(1): 212. DOI: 10.1186/s12876-021-01782-w.
[10]	Li H, Guo M, An Z, et al. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China[J]. Int J Environ Res Public Health, 2020, 17(6): 1818. DOI: 10.3390/ijerph17061818.
[11]	Liu D, Shen Y, Zhang R, et al. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China[J]. J Gastroenterol Hepatol, 2020, 36(6): 1670-1678. DOI: 10.1111/jgh.15320.
[12]	Eguchi Y, Hyogo H, Ono M, et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study[J]. J Gastroenterol, 2012, 47(5): 586-595. DOI: 10.1007/s00535-012-0533-z.
[13]	Lai X, Yang L, Legare S, et al. Dose-response relationship between serum uric acid levels and risk of incident coronary heart disease in the Dongfeng-Tongji Cohort[J]. Int J Cardiol, 2016, 224: 299-304. DOI: 10.1016/j.ijcard.2016.09.035.
[14]	Wong WV, Wong GL, Woo J, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease[J]. Clin Gastroenterol Hepatol, 2021, 19(10): 2161-2171. DOI: 10.1016/j.cgh.2020.10.046.
[15]	Zhou YJ, Li YY, Nie YQ, et al. Prevalence of fatty liver disease and its risk factors in the population of South China[J]. World J Gastroenterol, 2007, 13(47): 6419-6424. DOI: 10.3748/wjg.v13.i47.6419.
[16]	Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography[J]. Gut, 2012, 61(3): 409-415. DOI: 10.1136/gutjnl-2011-300342.
[17]	Park SH, Jeon WK, Kim SH, et al. Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults[J]. J Gastroenterol Hepatol, 2006, 21(1 Pt 1): 138-143. DOI: 10.1111/j.1440-1746.2005.04086.x.
[18]	Yoneda M, Thomas E, Sumida Y, et al. The influence of menopause on the development of hepatic fibrosis in nonobese women with nonalcoholic fatty liver disease[J]. Hepatology, 2014, 60(5): 1792. DOI: 10.1002/hep.27097.
[19]	Yang JD, Abdelmalek MF, Pang H, et al. Gender and menopause impact severity of fibrosis among patients with nonalcoholic steatohepatitis[J]. Hepatology, 2014, 59(4): 1406-1414. DOI: 10.1002/hep.26761.
[20]	Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American association for the study of liver diseases[J]. Hepatology, 2018, 67(1): 328-357. DOI: 10.1002/hep.29367.
[21]	Dietrich P, Hellerbrand C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome[J]. Best Pract Res Clin Gastroenterol, 2014, 28(4): 637-653. DOI: 10.1016/j.bpg.2014.07.008.
[22]	Mantovani A, Byrne CD, Bonora E, et al. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis[J]. Diabetes Care, 2018, 41(2): 372-382. DOI: 10.2337/dc17-1902.